Biovest International Inc.(fka BVTIQ)

[oregon 1]

This stock has run up so much in a short period of time . Just a little consolidation. This will go back up.

[medge1]

Why the sell off ?

[oregon 1]

Time for buying.

[erinihub]

you must be able to see the future :) BVTI is really being pumped on other sites, and people were getting a little too excited about it, imo, the price ran up so fast, we needed a little pull back...GL...looking forward to a lot more from this and abpiq

[klinkoo]

we are not at all that far, BLA for BiovaxID will be submitted in June this year for a fast approval before end of 2010. out of BK with a great improved balance sheet, shares intact, hopefully no dilution or very light and a major contract for AutovaxID in Q1 2010, and do you think this is a price manipulation?? this is going to 3$ with no time and 5$ before june.

[RunnersDad]

I am a firm believer in this company and it's pipeline, but wasn't expecting such a huge run up in price this quickly. We are still a while away from an FDA decision.
What does everyone think about today's gains? Price manipulation or simply eager investor's finally figuring out that this stock is a winner? Think we will see a big pullback in the next couple days?

[milehighbuck]

$2.00 at the close !!!!!!!!!!!!

[erinihub]

I am holding both...just trying to get extra shares as well...I had bvti at .35 a long time ago...wish i still had those shares...oh well, am expecting a lot to come. GL!

[Mutzman]

because ABPIQ is the majority shareholder of BVTI, whats good for one is good for the other. I own 3:2 ratio of ABPIQ:BVTI. I would NOT however be trading any of these if i was you. buy and accumulate BOTH, and HOLD on to them..!!! imho

[Mutzman]

because ABPIQ is the majority shareholder of BVTI, whats good for one is good for the other. I own 3:2 ratio of ABPIQ:BVTI. I would NOT however be trading any of these if i was you. buy and accumulate BOTH, and HOLD on to them..!!! imho

[erinihub]

ABPIQ...I am trading that as well...BVTI shares will be converted into that possibly? Any thoughts? TIA

[klinkoo]

not before 3$

[MoneyBroke]

Continues to go up. Where does it level off?

[Mutzman]

we are here.. have to like the price action! This is only the start of whats to come!!

[allchipin]

y $ 10. bla filing, bk emergence & approval of dndn. cud be more than we bargained for. check nwbo its a sleeper right now.

[allchipin]

y $ 10. bla filing, bk emergence & approval of dndn. cud be more than we bargained for. check nwbo its a sleeper right now.

[milehighbuck]

This is getting interesting !!! Anyone out there ???? $10.00 coming soon.

[milehighbuck]

YES !!!!!!!!! And there it is !!!!!!!!

[milehighbuck]

Can we hit a buck ?????? Come on baby !!!!

[milehighbuck]

Think Dendreon !!!!!!!!!!!!

[Mutzman]

The release will be on or before the end of Q1, so they have to the end of this month. AND IT WILL BE GREAT NEWS..! Im curious as to Why you said the 11th..?

[prado]

Hey klinkoo, none taken. I'm actually trying to learn what's going on here and it seems like you have a good handle on things. One day I was just sifting through some different stocks and I really wasn't sure what it was that I had found except that it looked interesting.

I'm sure that this info is somewhere on the board already, but I didn't spend the time looking for it.

Thanks for the insights as to what is happening here. I look forward to reading more of your posts and best of luck.

[klinkoo]

The final reorg plan should be released before March 11th.

[milehighbuck]

This will get very interesting once they come out of bankruptcy reorganization. Should not be much longer.

[klinkoo]

Yea sorry Prado, I didn't mean to be disrespect here, but Mentor is invested in BVTI since last year, the news from January is just a recurrent news about how their portfolio is doing well. I haven't checked all the posts yet in this board and I didn't know it hasn't been mentioned yet.

My humble apologize.

[prado]

How long is awhile? I posted that back in January and you joined Ihub in February.

"Yes we all knew that for a while"

[klinkoo]

Yes we all knew that for a while, Mentor Capital only choose carefully companies they invest on, thats a proof of confidence to see them invested in BioVest.

[prado]

Found this news today which might be of interest to you all here (Maybe you already knew about this).

Mentor Capital Takes Investment Position in Each of 10 Cancer Immunotherapy Index Companies

Jan 19, 2010
Pink OTC Markets News Service

San Diego, CA — Mentor Capital, Inc. (Pink Sheets:MNTR) has completed the set-up and initial funding of the Cancer Immunotherapy Index Fund. Through the CII Fund, Mentor Capital has now taken an initial equity position in each of the ten companies that make up Mentor Capital's proprietary Cancer Immunotherapy Index. The equally weighted CI Index was first created by Mentor Capital to track the growth of the cancer immunotherapy sector on an information basis. Since its formation in July 2009, the CI Index has appreciated at an approximate 100% annualized rate.
The Mentor Capital directed CII Fund invests in all ten companies in the CI Index. In an attempt to further increase return, Mentor Capital will begin to significantly overweight CI Fund investment into those CI Index companies that show the greatest medical and financial promise. Mentor Capital has authorization to raise approximately $130 Million in additional equity capital which is all slated for investment into the CII Fund.

The ten companies that Mentor Capital has invested in include Immunocellular Therapuetics, Ltd. (OTCBB:IMUC), Dendreon (NASDAQ:DNDN), Oncothyreon (NASDAQ:ONTY), Antigenics (NASDAQ:AGEN), Biovest International (BVTI.PK), Celldex Therapeutics (NASDAQ:CLDX), Northwest Biotherapeutics (OTCBB:NWBO), CEL – SCI Corp. (AMEX:CVM) and Generex Biotechnology (NASDAQ:GNBT) as a proxy for its wholly-owned immunotherapeutic subsidiary, Antigen Express, and Quantum Immunologics, Inc. a private company.

In cancer immunotherapy the patient's own immune system is trained to identify and attack cancer cells as the body normally does for any invading microbe. This approach avoids the severely negative effects of surgeries, chemotherapy and radiation.



Additional information on Mentor Capital plus listings and links to all Cancer Immunotherapy Index companies may be referenced from the company website: www.MentorCapital.com.



Forward Looking Statements, Safe Harbor and Risk Descriptions are Incorporated by Reference from the MNTR Company Web Site above.


For further information contact:



Chet Billingsley, CEO

Mentor Capital, Inc.

P.O. Box 1709

Ramona, CA 92065



(760) 788 - 4700

[Hardwood]

come to papa!!!!!!!

[Hardwood]

Agreed.. hands are tied but I'm giving IOU's.. I'm being serious.. I owe humanity.

[Hawks_Stocks]

To The Board:


Reminder of the huge relief effort for the Haitians for monetary contributions is much appreciated.

IHUB posted a banner and more information. (underneath the above menu bar)

Thanks for your time and interest!

[Chartbreaker1]

Great News !
This will go easy to 1,20 - 1,50 next week.
IMO.

Chart.

[fink]

FDA always do get a spoil frrom the MMs. They let it run just to short the snot out of em. I hope all were selling for a base of free shares.
Its the way you have to play these.
Now give me a 501K approval with a marketing partner coming in with a cash infusion and these fly.
Orpan status is good for the time line, but its a snall population of patients, hence the getty up on the time.
GENZ has built a power house on orphan status drugs.
Ya got time to buy back in after it falls. Probably have a few more times to fliup for even more free shares to ride into that big FDA unknown approval letter.

[milehighbuck]

It is a theraputic vaccine. So it is administered after the fact, not before you get the disease. They make the personalized vaccine with each patients own tumor cells.

[milehighbuck]

Hopefully BVTI can catch up with Dendreon. They are at $30.30 !!!

[Hawks_Stocks]

FDA Grants Orphan Drug Status for Personalized Lymphoma Vaccine

Biovest International, Inc. (Other OTC: BVTI) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to BiovaxID®, Biovest’s personalized lymphoma vaccine. BiovaxID represents a new class of active immunotherapy and is one of the few select late-stage patient-specific cancer vaccines vying to be among the first to reach market

With FDA Orphan Drug Status, Biovest has a seven-year period of market exclusivity for BiovaxID upon approval, thereby offering competitive protection from similar drugs of the same class. Orphan Drug Status also provides Biovest with eligibility to receive potential tax credit benefits, potential grant funding for research and development and significantly reduced filing fees for marketing applications. Based on statistically significant Phase III study data demonstrating an extended disease-free survival benefit, Biovest expects to file a Biologic License Application (BLA) with the FDA by approximately mid-year in order to seek U.S. approval of BiovaxID. The Company also expects to file regulatory applications seeking approvals in Europe and Canada

In other news, Biovest announced that the Company will present at the Biotechnology Showcase to be held in San Francisco next week, running concurrent with the JP Morgan 28th Annual Healthcare Conference

Event: Biotechnology Showcase™ 2010 Place: Marines’ Memorial Club & Hotel, San Francisco Biovest Presentation Day/Time: Wednesday, January 13th at 9:00 a.m. (PST) Conference Website: www.ebdgroup.com/bts/ If qualified investors or corporate partnering candidates are interested in scheduling a meeting with Biovest in San Francisco, please contact Douglas Calder at 813-864-2558 or [e-mail]

According to Biovest’s President, Mr. Samuel S. Duffey, the Biotechnology Showcase kicks off the year with an opportunity to update institutional investors, bankers and analysts as the Company prepares to emerge from reorganization. “We expect to make announcements in the near future that will demonstrate that we have taken full advantage of the reorganization process in restructuring debt and contractual obligations. We anticipate emerging from reorganization in the first part of 2010 with our current shareholder base successfully preserved and with a greatly improved balance sheet, which will enable management to focus on executing our business and drug development plans,” stated, Mr. Duffey

About Biovest International, Inc. Biovest International, Inc. is an emerging leader in the field of personalized immunotherapies targeting life-threatening cancers of the blood system. Developed in collaboration with the National Cancer Institute, BiovaxID® is a patient-specific, anti-lymphoma cancer vaccine, demonstrating statistically significant Phase III clinical benefit by prolonging disease-free survival in patients suffering from indolent follicular non-Hodgkin’s lymphoma. Biovest has developed and markets a proprietary line of automated hollow fiber bioreactor systems, including the innovative AutovaxID® which is a production platform for the scalable manufacture of difficult-to-produce biologics including personalized medicines, monoclonal antibodies, cell culture vaccines and therapeutics targeting highly infectious agents. Since 1981, Biovest has been offering its clients a wide range of instrumentation and cell culture contract manufacturing services. Headquartered in Tampa, Florida with its bio-manufacturing facility based in Minneapolis, Minnesota, Biovest is publicly-traded on the Over-the-Counter (OTC) market with the stock-ticker symbol “BVTI”, and is a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (Other OTC: ABPIQ)

[Hardwood]

Congrats here. Remember to lokc in your profits when you feel comfortable.. glta

[Mutzman]

BVTI is going to change the way we practice medicine. this is the first and only "patient specific" form of treating a major debilitating disease. their proprietary technology will be basis for how we move forward to treat any and all forms of diseases. bvti is a wholly owned subsidiary of ABPIQ. the only reason this stock is trading the way it is, is because of the "q" behind that ticker. which according to the recent pr and street chatter, they will be emerging with current shareholder intact. that and the stellar phase 3 results, named patient basis in eu, orphan drug status (which means the fda loves this treatment)and impending fda approval, we'll have two $30 stocks.!!!! buy buy buy ABPIQ BVTI

[Hawks_Stocks]

That's weird, cause as I was lurking through this and APBI's ghost towns, I had a vibe of Hedgefund going through my mind..lol

[Mr_Lotto3000]

short sellers are bringing this one down imo..

[Hawks_Stocks]

Yeah, I did mis read the first PR.. but I am glad and I still would have bought..lol It's a big if right now, but they have tested it in Europe and it showed promise.. (europe is usually our guinea pigs..lol) The sales for an lymphoma cancer vaccine would be HUGE.. Vaccines are huge, everyone gets them before they get the problem.. Heck, I would get it..lol

[Mr_Lotto3000]

waiting for the second piece of the pie for sure. dollar range for sure when they get official approval

[Hawks_Stocks]

This could be big... Makes you wonder why this and the APBI board are abandoned.. This is a sub of a NASDAQ company... I have drill tomorrow and see if the Doc's know of Accentia, and if they know where FDA Approvals get published first...

[Mr_Lotto3000]

lol ghost town for sure..

[Hawks_Stocks]

So we are emerging from bankruptcy, have 2.5 million in cash, expanding business in expectation of FDA approval (and a cancer vaccine, the FDA may just rush this a little).. Man, if this gets approved.. I better shut up so I can buy more..lol

[Hawks_Stocks]

Seems that this is a Subsidiary of APBI..

http://www.bizjournals.com/stlouis/stories/2010/01/04/daily64.html?ana=from_rss&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+bizj_stlouis+%28St.+Louis+Business+Journal%29

Notice this part..

In return, Accentia will give BioDelivery Sciences a warrant to purchase 2 million shares of Biovest, the SEC filing said.

And I am partial to this part:

Much of the focus is on BiovaxID, a personalized anti-lymphoma cancer vaccine that stimulates a patient’s own immune system to recognize and destroy cancerous cells. Early results from a Phase III clinical trial were promising, and additional data is expected to be filed in the next few months that could speed approval of the drug.

In anticipation of BiovaxID approvals, the company has started to expand a facility in Minneapolis where it will produce the vaccine.

[Hawks_Stocks]

The last Statement of Changes in Beneficial Ownership shows a heck of a lot of insider acquisition... Very weird this is... Must dig deeper over the weekend..lol

[Hawks_Stocks]

The interesting part of this board as it seems like we just walked into a ghost town.. Previous life, signs of recent activity then pooff.. Asteroid? I will dedicate some time to Due diligence this weekend..

[Hawks_Stocks]

Yes, the previous resistance seems to be at .75 and it appeared to be that on the Level 2 yesterday for a while.. If it gets a close above .75 the chartists will like this. I am however buying this purely based on fundamentals..The recent news is what caught my attention..

[Hawks_Stocks]

I didn't even check out the board since you said it was slow..lol If i knew you were here..